On August 3rd, Zoetis announced that they received a conditional licnese from the United States Department of Agriculture (USDA) for Canine Atopic Dermatitis Immunotherapeutic. Canine Atopic Dermatitis Immunotherapeutic is an antibody therapy that is designed to reduce clinical signs associated with atopic dermatitis in dogs. The USDA is currently only offering conditional licenses for biological products for canine atopic dermatitis. Zoetis is working towards a full license for Canine Atopic Dermatitis Immunotherapeutic.
Canine Atopic Dermatitis Immunotherapeutic “contains an antibody that specifically targets and neutralizes interleukin-31 (IL-31), a key protein that is responsible for sending the itch signal to the brain. It will be available in a ready-to-use, sterile liquid administered as a once-monthly subcutaneous injection and will help provide sustained relief from the itching associated with atopic dermatitis in dogs of any age.”
Veterinary dermatologist, Dr. Thomas Lewis II said, “The introduction of Canine Atopic Dermatitis Immunotherapeutic will provide veterinarians an innovative new option to address this very challenging skin condition. By helping to relieve itching and the clinical signs associated with atopic dermatitis in affected dogs, it will also help restore quality of life for both atopic dogs and the people who love them.”
Zoetis already manufactures Apoquel, a medication for the control of pruritus associated with allergic dermatitis and the control of atopic dermatitis in dogs. According to Zoetis, Canine Atopic Dermatitis Immunotherapeutic “represents another major innovation to emerge from the proprietary research and development platform Zoetis has built based on new scientific insights into the pathway of allergic skin conditions.”
Executive Vice President and President of Research and Development at Zoetis, Catherine Knupp said, “We have been active in building a research platform in monoclonal antibodies that will have a broad application across species and medical conditions. This first product from that platform builds on our knowledge base in the area of canine dermatology and further reinforces our dedication to developing innovative dermatology solutions.”
Canine Atopic Dermatitis Immunotherapeutic will become available to veterinary dermatologists in the fourth quarter of 2015.
No comments:
Post a Comment